GRAL

GRAIL, Inc.

NasdaqGSUSDEQUITY DELAYED

79.27

▲ 1.30 (1.67%)

MARKET · —

Price

Open

77.19

Prev close

77.97

Day high

80.76

Day low

76.15

Volume

593.29K

Market cap

—

P/E (TTM)

—

52W range

30.82 – 118.84

Trailing performance

Price return · vs SPY

Returnvs SPY

+17.19% +18.6%

+13.05% +9.3%

+17.21% +14.1%

+58.41% +47.3%

YTD

-7.07% -19.4%

+147.25% +127.3%

— -74.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

72.77

+8.94% from price

SMA 20

70.60

+12.66% from price

SMA 50

68.75

+15.69% from price

SMA 100

63.22

+25.39% from price

SMA 200

73.30

+8.51% from price

EMA 12

72.96

+8.64% from price

EMA 26

71.16

+11.40% from price

EMA 50

69.11

+14.71% from price

RSI (14)

61.9

Neutral

MACD (12,26,9)

1.81

Hist 0.82

ATR (14)

5.46

6.87% of price

Realised vol 30D

82.4%

Annualised

Bollinger upper

79.35

20, 2σ

Bollinger lower

61.85

20, 2σ

50 / 200 cross

Death

68.75 vs 73.30

Trend bias

Above 200

+8.51%

Risk profile

Daily returns · 1Y window

Beta vs SPY

2.63

More volatile than market

Correlation to SPY

0.34

Loosely linked

Realised vol 30D

82.4%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-62.9%

Peak to trough

Max drawdown 5Y

-62.9%

Peak to trough

ATR 14

5.46

6.87% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 79.27

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

GRAL · links out to the publisher

GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting MarketBeat · 9d ago GRAIL (GRAL) Q2 2026 Earnings Call Transcript Motley Fool · 9d ago Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? Simply Wall St. · 15d ago GRAIL's Galleri Blood Test to Be Evaluated by US FDA Advisory Panel MT Newswires · 15d ago GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test PR Newswire · 15d ago Why BillionToOne Plummeted 38%, Leading A Medtech Sell-Off Investor's Business Daily · 16d ago GRAIL, Inc. Q2 2026 Earnings Call Summary Moby · 16d ago GRAIL Inc (GRAL) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... GuruFocus.com · 17d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.